Your browser is no longer supported. Please, upgrade your browser.
Settings
AVDL [NASD]
Avadel Pharmaceuticals plc
Index- P/E- EPS (ttm)-0.96 Insider Own1.07% Shs Outstand58.49M Perf Week15.09%
Market Cap537.10M Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float35.53M Perf Month11.59%
Income-56.00M PEG- EPS next Q-0.38 Inst Own57.80% Short Float10.37% Perf Quarter26.21%
Sales0.00M P/S- EPS this Y95.70% Inst Trans-0.59% Short Ratio12.37 Perf Half Y3.04%
Book/sh2.03 P/B4.51 EPS next Y75.60% ROA-18.40% Target Price- Perf Year82.27%
Cash/sh3.48 P/C2.63 EPS next 5Y15.00% ROE-38.00% 52W Range4.83 - 10.32 Perf YTD36.98%
Dividend- P/FCF- EPS past 5Y-15.30% ROI3.00% 52W High-11.38% Beta1.30
Dividend %- Quick Ratio- Sales past 5Y-33.60% Gross Margin- 52W Low89.44% ATR0.42
Employees32 Current Ratio14.20 Sales Q/Q- Oper. Margin- RSI (14)73.85 Volatility6.15% 4.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-175.80% Profit Margin- Rel Volume2.21 Prev Close9.17
ShortableYes LT Debt/Eq1.19 EarningsAug 09 BMO Payout- Avg Volume297.85K Price9.15
Recom1.40 SMA2012.75% SMA5016.62% SMA20016.68% Volume658,556 Change-0.22%
Sep-23-21Initiated Needham Buy $17
Jul-31-20Initiated Oppenheimer Outperform $19
Jul-21-20Initiated SVB Leerink Outperform $17
Jun-30-20Initiated H.C. Wainwright Buy $15
Apr-03-20Initiated Jefferies Buy $14
Mar-12-20Initiated Stifel Buy $14
Feb-26-20Initiated Piper Sandler Overweight $14
Jan-30-20Initiated Craig Hallum Buy $15
Jun-14-19Upgrade Ladenburg Thalmann Neutral → Buy $6
Feb-08-19Downgrade Ladenburg Thalmann Buy → Neutral
Sep-20-21 08:00AM  
Sep-03-21 09:32AM  
Sep-02-21 08:00AM  
Aug-26-21 06:14AM  
Aug-16-21 08:00AM  
Aug-09-21 02:30PM  
08:00AM  
Aug-02-21 08:00AM  
Jul-07-21 08:00AM  
Jun-27-21 03:36AM  
Jun-09-21 09:00AM  
Jun-03-21 08:00AM  
Jun-02-21 08:00AM  
May-25-21 08:00AM  
May-13-21 02:00AM  
May-10-21 06:00PM  
08:00AM  
06:45AM  
Apr-29-21 08:00AM  
Apr-19-21 07:05AM  
Apr-17-21 08:00AM  
Apr-08-21 08:00AM  
Mar-29-21 01:22AM  
Mar-18-21 08:00AM  
Mar-09-21 03:00PM  
07:00AM  
05:30AM  
Mar-04-21 08:00AM  
Mar-02-21 08:00AM  
Mar-01-21 12:10PM  
08:00AM  
Feb-25-21 08:00AM  
Feb-23-21 06:20PM  
Feb-17-21 08:00AM  
Feb-10-21 08:00AM  
Dec-28-20 11:47PM  
Dec-16-20 02:21PM  
08:00AM  
Dec-15-20 08:00AM  
Dec-07-20 08:00AM  
Nov-23-20 08:00AM  
Nov-11-20 08:00AM  
Nov-09-20 06:30PM  
07:00AM  
06:30AM  
Oct-26-20 08:00AM  
Oct-07-20 10:38AM  
Sep-30-20 06:58AM  
Sep-17-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 04:35PM  
Aug-18-20 08:42AM  
Aug-11-20 01:30AM  
Aug-10-20 08:34AM  
08:00AM  
Aug-05-20 03:31PM  
Aug-01-20 08:12AM  
Jul-27-20 08:00AM  
Jul-13-20 08:00AM  
Jul-03-20 07:05AM  
Jul-01-20 08:00AM  
Jun-27-20 09:13PM  
Jun-08-20 08:00AM  
Jun-01-20 09:20AM  
08:00AM  
May-28-20 05:54AM  
May-11-20 02:30PM  
10:17AM  
07:00AM  
May-09-20 08:10AM  
May-06-20 07:04AM  
May-04-20 04:05PM  
Apr-28-20 08:28PM  
12:55PM  
10:48AM  
07:36AM  
Apr-27-20 06:07PM  
04:20PM  
10:38AM  
07:00AM  
Apr-23-20 08:46AM  
Apr-15-20 09:23AM  
Apr-08-20 10:02AM  
Mar-25-20 08:00AM  
Mar-14-20 08:26AM  
Mar-13-20 06:56AM  
Mar-12-20 07:00AM  
06:30AM  
Mar-11-20 12:27PM  
Feb-27-20 08:30AM  
08:00AM  
Feb-21-20 09:00AM  
Jan-28-20 02:59AM  
Jan-23-20 10:42AM  
Jan-21-20 08:41AM  
Jan-13-20 05:26AM  
Jan-10-20 08:00AM  
Jan-06-20 12:00PM  
Dec-23-19 07:54AM  
Dec-19-19 11:15AM  
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.